Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous glucose monitor maker’s facilities last year.

"DexCom, Inc. (NASDAQ:DXCM) was a significant detractor from absolute and relative results in 2024, which we attribute to a combination of poor execution and fears of disruption by GLP-1 drugs.

Dexcom’s version of this is its ability to maintain an obsessive focus on the problem it was founded to solve, while fighting off the insularity and incrementalism that so often go along with ...

(Reuters) -Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its ...

DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now. Going into 2024, DexCom 's (DXCM 1.48%) shares were up a whopping 14 times over the last 10 years.

DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice ...

DexCom Inc (DXCM) reports 14% organic revenue growth and announces a $750 million share repurchase program, despite facing supply chain issues and FDA warnings.

Dexcom, a continuous glucose monitoring (CGM) systems company, announced Thursday that its G7 system has been cleared by the US Food and Drug Administration. Suitable for people with Type 1, Type ...

DexCom's stock crashed after the company lowered its guidance last quarter. The rationale for the adjustment was a bit concerning, prompting analysts to wonder if there are greater problems facing ...